Intra-arterial chemotherapy with gemcitabine and cisplatin for patients with recurrence of transitional cell carcinoma confined to the pelvis

J Chemother. 2009 Feb;21(1):91-7. doi: 10.1179/joc.2009.21.1.91.

Abstract

Post-cystectomy recurrence of transitional-cell carcinoma (TCC) that is confined to the pelvis is uncommon, and few data exist to guide its management. we used weekly intra-arterial chemotherapy with gemcitabine and cisplatin in a consecutive series of 11 patients with this diagnosis. After 2 cycles of intra-arterial chemotherapy with gemcitabine (each cycle: 900 mg/m(2) on days 1, 8, and 15) plus cisplatin (each cycle: 30 mg/m(2) on days 1, 8, and 15), 3 patients achieved complete response (CR) and 8 patients partial response (PR). two pR patients achieved CR after surgery and radiotherapy for residual disease. Six pR patients died of disease progression 8 to 20 months after chemotherapy. Four CR patients have survived, free of disease, 17 to 43 months, and 1 CR patient died of a non-tumor-related cause 23 months after chemotherapy. Short course intra-arterial chemotherapy with a GC regimen thus appears to be highly effective in the subset of patients with recurrent TCC confined to the pelvis.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / mortality
  • Carcinoma, Transitional Cell / secondary
  • Cisplatin / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Female
  • Gemcitabine
  • Humans
  • Infusions, Intra-Arterial*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Pelvic Neoplasms / drug therapy*
  • Pelvic Neoplasms / secondary
  • Tomography, X-Ray Computed
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology

Substances

  • Deoxycytidine
  • Cisplatin
  • Gemcitabine